Transcriptome-based repurposing of apigenin as a potential anti-fibrotic agent targeting hepatic stellate cells

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Hicks, Daniel F ^a   Goossens, Nicolas ^a,b   Blas García, Ana ^a,c   Tsuchida, Takuma ^a,d   Wooden, Benjamin ^a   Wallace, Michael C ^a,e   Nieto, Natalia ^f   Lade, Abigale ^a   Redhead, Benjamin ^a   Cederbaum, Arthur I ^a   Dudley, Joel T ^a   Fuchs, Bryan C ^g   Lee, Youngmin A ^a   Hoshida, Yujin ^a   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF VALENCIA   (Spain)

^d MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APIGENIN; BIOLOGICAL MARKER; TRANSCRIPTOME;

ANIMAL; CELL LINE; DRUG DEVELOPMENT; DRUG EFFECT; DRUG REPOSITIONING; HEPATIC STELLATE CELL; HUMAN; METABOLISM; MOUSE;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; APIGENIN; BIOMARKERS; CELL LINE; DRUG DISCOVERY; DRUG REPOSITIONING; HEPATIC STELLATE CELLS; HUMANS; MICE; TRANSCRIPTOME;

EID: 85014712005     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42563     Document Type: Article

References (47)

1. Mederacke, I. et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fbrosis independent of its aetiology. Nat Commun 4, 2823 (2013).
2. Trautwein, C., Friedman, S. L., Schuppan, D. & Pinzani, M. Hepatic fbrosis: Concept to treatment. J Hepatol 62, S15-24 (2015).
3. Wooden, B., Goossens, N., Hoshida, Y. & Friedman, S. L. Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology 152, 53-67 e53 (2017).
4. Blaauboer, M. E. et al. Novel combination of collagen dynamics analysis and transcriptional profling reveals fbrosis-relevant genes and pathways. Matrix Biol 32, 424-431 (2013).
5. Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69, 7385-7392 (2009).
6. Hoshida, Y. et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 144, 1024-1030 (2013).
7. Hoshida, Y. et al. Gene expression in fxed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359, 1995-2004 (2008).
8. Zhang, D. Y. et al. A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma afer curative resection. Gut 65, 1754-1764 (2016).
9. Fuchs, B. C. et al. Epidermal growth factor receptor inhibition attenuates liver fbrosis and development of hepatocellular carcinoma. Hepatology 59, 1577-1590 (2014).
10. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
11. Shibata, N. et al. Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies. Cell transplantation 12, 499-507 (2003).
12. Friedman, S. L. & Roll, F. J. Isolation and culture of hepatic lipocytes, Kupfer cells, and sinusoidal endothelial cells by density gradient centrifugation with Stractan. Analytical biochemistry 161, 207-218 (1987).
13. Chen, Y. et al. Hedgehog controls hepatic stellate cell fate by regulating metabolism. Gastroenterology 143, 1319-1329 e1311-1311 (2012).
14. Tabut, D. et al. Complementary vascular and matrix regulatory pathways underlie the benefcial mechanism of action of sorafenib in liver fbrosis. Hepatology 54, 573-585 (2011).
15. Bridle, K. R. et al. Rapamycin inhibits hepatic fbrosis in rats by attenuating multiple profbrogenic pathways. Liver Transplantation 15, 1315-1324 (2009).
16. Chen, H. et al. Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fbrosis in vivo. Bioorganic & medicinal chemistry 22, 3393-3404 (2014).
17. Mrazek, A. A. et al. Apigenin inhibits pancreatic stellate cell activity in pancreatitis. Journal of Surgical Research 196, 8-16 (2015).
18. Arango, D. et al. Molecular basis for the action of a dietary favonoid revealed by the comprehensive identifcation of apigenin human targets. Proc Natl Acad Sci USA 110, E2153-2162 (2013).
19. Wong, G. W. et al. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose-tissue-selective expression patterns, regulation by PPAR-gamma agonist, cysteine-mediated oligomerizations, combinatorial associations and metabolic functions. Biochem J 416, 161-177 (2008).
20. Lieber, C. S. & DeCarli, L. M. The feeding of alcohol in liquid diets: two decades of applications and 1982 update. Alcohol Clin Exp Res 6, 523-531 (1982).
21. Pugh, R. N., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60, 646-649 (1973).
22. Chen, H. et al. Design, synthesis, and characterization of novel apigenin analogues that suppress pancreatic stellate cell proliferation in vitro and associated pancreatic fbrosis in vivo. Bioorg Med Chem 22, 3393-3404 (2014).
23. Mrazek, A. A. et al. Apigenin inhibits pancreatic stellate cell activity in pancreatitis. J Surg Res 196, 8-16 (2015).
24. Shukla, S. & Gupta, S. Apigenin: a promising molecule for cancer prevention. Pharmaceutical research 27, 962-978 (2010).
25. Schafer, A. & Buechler, C. CTRP family: linking immunity to metabolism. Trends Endocrinol Metab 23, 194-204 (2012).
26. Rohrbach, S., Aurich, A. C., Li, L. & Niemann, B. Age-associated loss in adiponectin-activation by caloric restriction: lack of compensation by enhanced inducibility of adiponectin paralogs CTRP2 and CTRP7. Mol Cell Endocrinol 277, 26-34 (2007).
27. Wong, G. W., Wang, J., Hug, C., Tsao, T.-S. & Lodish, H. F. A family of Acrp30/adiponectin structural and functional paralogs. Proceedings of the National Academy of Sciences of the United States of America 101, 10302-10307 (2004).
28. Peterson, J. M., Seldin, M. M., Tan, S. Y. & Wong, G. W. CTRP2 overexpression improves insulin and lipid tolerance in diet-induced obese mice. PLoS One 9, e88535 (2014).
29. Smolen, J. S. et al. Efcacy and safety of lefunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. The Lancet 353, 259-266 (1999).
30. Lane, I., Lumley, P., Michael, M., Peters, A. & McCollum, C. A specifc thromboxane receptor blocking drug, AH23848, reduces platelet deposition on vascular grafs in man. Trombosis and haemostasis 64, 369-373 (1990).
31. De Bono, D. P. et al. Effect of the specifc thromboxane receptor blocking drug AH23848 in patients with angina pectoris. British heart journal 56, 509-517 (1986).
32. German & Group, A.X.S. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The Lancet 331, 489-493 (1988).
33. Rougier, P. et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fuorouracil-based chemotherapy. Journal of Clinical Oncology 15, 251-260 (1997).
34. Pareek, A., Chandanwale, A., Oak, J., Jain, U. & Kapoor, S. Efcacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac-an Indian experience. Current medical research and opinion 22, 977-988 (2006).
35. Sandoval, M. A. & Hernandez-Vaquero, D. Preventing peridural fbrosis with nonsteroidal anti-infammatory drugs. European Spine Journal 17, 451-455 (2008).
36. Singh, G., Radhakrishnan, G. & Guleria, K. Comparison of sublingual misoprostol, intravenous oxytocin, and intravenous methylergometrine in active management of the third stage of labor. International Journal of Gynecology & Obstetrics 107, 130-134 (2009).
37. Bateman, B. et al. Methylergonovine Maleate and the Risk of Myocardial Ischemia and Infarction. Obstetric Anesthesia Digest 34, 214-215 (2014).
38. Chung, F.-H. et al. Gene-Set Local Hierarchical Clustering (GSLHC)-A Gene Set-Based Approach for Characterizing Bioactive Compounds in Terms of Biological Functional Groups. PloS one 10, e0139889 (2015).
39. Investigators, W.G.f.t.W.s.H.I. Risks and benefts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Jama 288, 321-333 (2002).
40. Janssen, K. et al. Effects of the favonoids quercetin and apigenin on hemostasis in healthy volunteers: results from an in vitro and a dietary supplement study. The American journal of clinical nutrition 67, 255-262 (1998).
41. Ma, G., Zhang, R., Ying, K. & Wang, D. Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data. Eur Rev Med Pharmacol Sci 19, 578-585 (2015).
42. Li, J. et al. Gene expression profling of CD133-positive cells in coronary artery disease. Molecular medicine reports 12, 7512-7516 (2015).
43. Balakumar, P. & Singh, M. Effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Int J Pharmacol 2, 543-548 (2006).
44. Huttunen, M. O. et al. Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatrica Scandinavica 91, 271-277 (1995).
45. Yoshitake, T., Asano, K., Yamamura, H., Yoshitake, J. & Arai, T. Experimental and clinical studies on the hemodynamic and metabolic effects of dibutyryl cyclic AMP. Progress in clinical and biological research 111, 211 (1983).
46. Miyagi, Y., Sasayama, S., Nakajima, H., Fujita, M. & Asanoi, H. Comparative hemodynamic effects of intravenous dobutamine and dibutyryl cyclic AMP, a new inotropic agent, in severe congestive heart failure. Journal of cardiovascular pharmacology 15, 138-143 (1990).
47. Kollros, P., Bates, S., Mathews, M., Horwitz, A. & Glagov, S. Cyclic AMP inhibits increased collagen production by cyclically stretched smooth muscle cells. Laboratory investigation; a journal of technical methods and pathology 56, 410-417 (1987).